$14.04
1.08% yesterday
Nasdaq, May 01, 10:00 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Stock price

$14.04
+1.84 15.03% 1M
-5.45 27.96% 6M
-4.76 25.32% YTD
-9.13 39.40% 1Y
-29.01 67.39% 3Y
-18.52 56.88% 5Y
+7.07 101.43% 10Y
Nasdaq, Closing price Thu, May 01 2025
+0.15 1.08%
ISIN
US04280A1007
Symbol
ARWR
Sector
Industry

Key metrics

Market capitalization $1.93b
Enterprise Value $2.25b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 900.21
P/S ratio (TTM) P/S ratio 771.17
P/B ratio (TTM) P/B ratio 33.52
Revenue growth (TTM) Revenue growth -98.62%
Revenue (TTM) Revenue $2.50m
EBIT (operating result TTM) EBIT $-625.95m
Free Cash Flow (TTM) Free Cash Flow $-576.61m
Cash position $552.94m
EPS (TTM) EPS $-5.15
P/E forward negative
P/S forward 6.46
EV/Sales forward 7.54
Short interest 11.80%
Show more

Is Arrowhead Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,788 stocks worldwide.

Arrowhead Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

10x Buy
71%
4x Hold
29%

Analyst Opinions

14 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Arrowhead Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2.50 2.50
99% 99%
100%
- Direct Costs 20 20
39% 39%
783%
-17 -17
110% 110%
-683%
- Selling and Administrative Expenses 80 80
1% 1%
3,218%
- Research and Development Expense 509 509
36% 36%
20,354%
-606 -606
113% 113%
-24,255%
- Depreciation and Amortization 20 20
39% 39%
783%
EBIT (Operating Income) EBIT -626 -626
109% 109%
-25,038%
Net Profit -640 -640
116% 116%
-25,588%

In millions USD.

Don't miss a Thing! We will send you all news about Arrowhead Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrowhead Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
one day ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page...
Neutral
Business Wire
16 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an em...
Neutral
Business Wire
27 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company's Board of Directors approved “inducement” grants to 21 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 re...
More Arrowhead Pharmaceuticals, Inc. News

Company Profile

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Head office United States
CEO Christopher Anzalone
Employees 609
Founded 1989
Website www.arrowheadpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today